miltefosine and Leishmaniasis, Cutaneous studies

miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.

Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.

Research Excerpts

Excerpt	Relevance	Reference
"To describe the characteristic clinical features and management of keratitis in the patients receiving miltefosine for post-kala-azar dermal leishmaniasis (PKDL)."	8.02	Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis. ( Ambasta, A; Arya, LK; Kusumesh, R; Mohan, N; Ravidas, V; Sinha, BP, 2021)
"Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year."	6.52	Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. ( Fujinami, N; Shah, PJ; Vakil, NH, 2015)
"Oral miltefosine was started at a dose of 150 mg/day but had to be stopped after 20 days as the patient developed diarrhea, bipedal edema, and renal impairment."	5.56	Case Report: Erysipeloid Cutaneous Leishmaniasis Treated with Oral Miltefosine. ( Adhikary, S; Karki, A; Parajuli, N; Tiwari, S, 2020)
" We reported a case of acute anterior uveitis,a rare adverse effect, experienced by a patient treated with miltefosine for post-kala-azar dermal leishmaniasis."	5.56	Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis. ( Das, P; Das, VNR; Lal, CS; Pal, B; Pandey, K; Topno, RK, 2020)
"Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas."	5.36	Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010)
"Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and paromomycin should be available for the treatment of visceral leishmaniasis (VL) within the next year, they all suffer from limitations of either cost, specific toxicities or parenteral administration."	4.83	Current scenario of drug development for leishmaniasis. ( Croft, SL; Seifert, K; Yardley, V, 2006)
"To describe the characteristic clinical features and management of keratitis in the patients receiving miltefosine for post-kala-azar dermal leishmaniasis (PKDL)."	4.02	Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis. ( Ambasta, A; Arya, LK; Kusumesh, R; Mohan, N; Ravidas, V; Sinha, BP, 2021)
" The presence of vesicles at the site of heat application was the most common adverse event reported associated with the use of TT; while vomiting (31."	3.11	A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World. ( Alvarez, F; Arana, B; Boni, M; Echevarria, J; Jiménez, A; Llanos-Cuentas, A; López, L; Méndez, C; Quintero, J; Ramos, AP; Rode, J; Tabares, Y; Valencia, B; Vélez, I, 2022)
"Miltefosine has proven efficacy for CL caused by L."	3.01	A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil. ( Barral, A; Barral-Netto, M; Boaventura, V; Carvalho, EM; Corte, TWF; Guimarães, LH; Lago, T; Machado, PRL; Penna, G; Prates, FVO; Schriefer, A, 2021)
" We aimed to characterize the intracellular PBMC miltefosine kinetics by developing a population pharmacokinetic (PK) model simultaneously describing plasma and intracellular PBMC pharmacokinetics."	2.87	Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. ( Beijnen, JH; Castro, MDM; Cossio, A; Dorlo, TPC; Gomez, MA; Kip, AE; Saravia, NG; Schellens, JHM, 2018)
"Miltefosine was found to be effective and safe in the treatment of PKDL."	2.80	Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. ( Chakravarty, J; Rai, M; Singh, A; Sundar, S, 2015)
" The adverse effects were primarily gastrointestinal for miltefosine and pain at the lesion site after treatment for thermotherapy."	2.78	Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. ( Cruz, C; Godoy, G; López, L; Robledo, SM; Vélez, ID, 2013)
"Oral miltefosine has not been evaluated for pediatric cutaneous leishmaniasis."	2.77	Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. ( Garcerant, D; Gore Saravia, N; Miranda, MC; Montero, LM; Muvdi Arenas, S; Nicholls, RS; Osorio, L; Pérez, M; Prager, M; Rodríguez-Barraquer, I; Rojas, MX; Rubiano, LC, 2012)
"Miltefosine is an oral agent used for cutaneous leishmaniasis treatment."	2.75	Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. ( López, L; Mestra, L; Rodríguez, E; Rojas, C; Sánchez, X; Vélez, I, 2010)
"Miltefosine was more effective than Sb(v) in the age group of 13-65 years-old compared to 2-12 years-old group (78."	2.75	Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. ( Ampuero, J; Carvalho, EM; Guimarães, LH; Machado, PR; Penna, G; Rocha, AT; Schriefer, A; Sousa, RS; Talhari, A; Villasboas, L, 2010)
" The safety of miltefosine-allopurinol combination therapy was confirmed by lack of effect on renal and hepatic parameters and adverse reactions."	2.74	Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. ( Bianciardi, P; Cañavate, C; Cruz, I; Miró, G; Mortarino, M; Oliva, G; Vischer, C, 2009)
" Population pharmacokinetic modeling was performed with nonlinear mixed-effect modeling, using NONMEM."	2.73	Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. ( Beijnen, JH; de Vries, HJ; de Vries, PJ; Dorlo, TP; Huitema, AD; Keizer, RJ; van Thiel, PP, 2008)
"Miltefosine appears to be a safe and effective alternative to currently used therapies."	2.73	Miltefosine in cutaneous leishmaniasis. ( Mumtaz, N; Rahman, SB; ul Bari, A, 2007)
"The miltefosine rate was lower than historic antimony cure rates of >90%."	2.71	Miltefosine for new world cutaneous leishmaniasis. ( Arana, BA; Arboleda, M; Berman, JD; Diaz, A; Engel, J; Gutierrez, P; Junge, K; Luz, M; Rizzo, N; Sindermann, H; Soto, J; Toledo, J; Vega, JC, 2004)
" In this uncontrolled study of oral miltefosine for treatment of patients with American cutaneous leishmaniasis, a dosage of approximately 2."	2.70	Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. ( Berman, J; Engel, J; Fischer, C; Gutierrez, P; Nicholls, RS; Padilla, J; Soto, J; Toledo, J; Voss, A, 2001)
" Moreover, VL and PKDL pharmacovigilance studies indicate a risk for serious adverse events, questioning the safety of MF."	2.61	The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis. ( den Boer, ML; Essink, DR; Pijpers, J; Ritmeijer, K, 2019)
"Conventional treatment of cutaneous leishmaniasis involves intravenous or intralesional pentavalent antimonials."	2.52	Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic. ( Burden-Teh, E; Williams, HC; Wootton, CI, 2015)
"Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year."	2.52	Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. ( Fujinami, N; Shah, PJ; Vakil, NH, 2015)
" These drugs were incorporated in conventional dosage forms or loaded in lipid nanocarries, which have been used mainly for improved skin delivery and antileishmanial activity."	2.48	Drug delivery systems for the topical treatment of cutaneous leishmaniasis. ( Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA, 2012)
"We report a 46-year-old patient with acquired immune deficiency syndrome who, 7 months after diagnosis of VL, developed PKDL and uveal leishmaniasis following HAART-induced immune recovery."	2.44	Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. ( Acquaviva, V; Antinori, S; Bestetti, G; Corbellino, M; Foschi, A; Longhi, E; Meroni, L; Parravicini, C; Piolini, R; Trovati, S, 2007)
"Miltefosine is a lecithin analogue and its mechanism may be to inhibit phosphatidylcholine biosynthesis in the causative parasites."	2.43	Miltefosine to treat leishmaniasis. ( Berman, J, 2005)
"Miltefosine was well tolerated, and as effective as historic values of antimony for treatment of L."	2.43	Treatment of New World cutaneous leishmaniasis with miltefosine. ( Berman, J; Soto, J, 2006)
"Miltefosine is an alkylphosphocholine, originally developed for the treatment of cancer."	2.43	[Miltefosine: a new remedy for leishmaniasis]. ( Beijnen, JH; de Vries, PJ; Dorlo, TP; Eggelte, TA, 2006)
"Recent developments in the treatment of simple cutaneous leishmaniasis are discussed followed by speculation about future therapies."	2.42	Cutaneous leishmaniasis: current and future management. ( Hepburn, NC, 2003)
" Following the confirmation of significant in vitro activity, the performance of the maximum tolerated dose of OLPC was evaluated in an experimental murine model of CL followed by a dose-response titration and the efficacy evaluation of four OLPC formulations (two with a fast-release and two with a slow-release profile) using bioluminescent Leishmania major parasites."	1.91	Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis. ( Alavijeh, M; Croft, SL; Dixon, J; Harris, A; Mcarthur, KN; Platteeuw, JJ; Van Bocxlaer, K; Van Den Heuvel, D; Yardley, V, 2023)
"Cutaneous leishmaniasis was not considered as an initial diagnosis because of the atypical appearance of the lesion as well as his residence in the hilly region of Nepal."	1.62	Case Report: An Atypical Erysipeloid Presentation of Cutaneous Leishmaniasis from the Hilly Region of Nepal. ( Nepal, S, 2021)
"Miltefosine was orally administered for 27 patients with MA resistant ACL with approved L."	1.62	The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial. ( Darchini-Maragheh, E; Goyonlo, VM; Kiafar, B; Layegh, P; Tayyebi, M, 2021)
"Treatment with miltefosine resulted in cure in 77 % (20/26) of cases, with cures among all species."	1.62	Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis. ( Brown, T; Nash, TE; Nutman, TB; O'Connell, EM; Talaat, KR; Ware, JM; Wetzler, L, 2021)
" We reported a case of acute anterior uveitis,a rare adverse effect, experienced by a patient treated with miltefosine for post-kala-azar dermal leishmaniasis."	1.56	Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis. ( Das, P; Das, VNR; Lal, CS; Pal, B; Pandey, K; Topno, RK, 2020)
"Oral miltefosine was started at a dose of 150 mg/day but had to be stopped after 20 days as the patient developed diarrhea, bipedal edema, and renal impairment."	1.56	Case Report: Erysipeloid Cutaneous Leishmaniasis Treated with Oral Miltefosine. ( Adhikary, S; Karki, A; Parajuli, N; Tiwari, S, 2020)
"Prompt identification and treatment of cutaneous leishmaniasis caused by species with potential for mucocutaneous spread are key to limiting morbidity and mortality."	1.56	Cutaneous leishmaniasis successfully treated with miltefosine. ( Call, JE; Chan, CX; Chapman, MS; Glass, JS; Simmons, BJ; Yan, S, 2020)
"In Brazil, cutaneous leishmaniasis is caused predominantly by L."	1.51	Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake. ( Alves, JM; Carvalho, EM; Coelho, AC; Cruz, AK; Cruz, MC; Espada, CR; Hornillos, V; Machado, PR; Magalhães, RM; Schriefer, A; Uliana, SRB, 2019)
"Topical treatment for cutaneous leishmaniasis (CL) would be useful for treatment of some forms of the disease."	1.51	Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis. ( Escobar, P; Mantilla, JC; Neira, LF, 2019)
"Miltefosine was efficacious, safe and well tolerated, suggesting that it can play an important role in the treatment of severe PKDL also in East-African patients."	1.51	Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient. ( Abongomera, C; Adera, C; Battaglioli, T; Ritmeijer, K, 2019)
" This study aimed to investigate the feasibility of using focused pharmacovigilance for VL (VLPV) in Bangladesh's National Kala-azar Elimination Programme for the early detection and prevention of expected and unexpected adverse drug reactions (ADRs)."	1.48	Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. ( Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V, 2018)
"Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated."	1.46	Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. ( Arrese Estrada, J; Cnops, L; Darcis, G; de Leval, L; Giot, JB; Hayette, MP; Leonard, P; Moutschen, M; Tassin, F; Van der Auwera, G, 2017)
"Oral miltefosine has been shown to be non-inferior to first-line, injectable meglumine antimoniate (MA) for the treatment of cutaneous leishmaniasis (CL) in children."	1.46	Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis. ( Bartlett, AH; Berger, BA; Castro, MDM; Cossio, A; Pho, MT; Prada, S; Saravia, NG, 2017)
"In the Netherlands, cutaneous leishmaniasis is most commonly seen in military personnel deployed on a mission or training abroad."	1.46	Two cases of cutaneous leishmaniasis in Dutch military personnel treated with oral miltefosine. ( Couwenberg, SM; Kortbeek, LM; Schadd, EM; Stijnis, C; van der Snoek, EM, 2017)
"Tamoxifen was able to hinder the emergence of miltefosine resistance."	1.43	Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. ( Coelho, AC; Reimão, JQ; Trinconi, CT; Uliana, SR, 2016)
"In this study 86 confirmed cases of PKDL were treated with two different dosage regimens of miltefosine (Regimen I- 50mg twice daily for 90 days and Regimen II- 50 mg thrice for 60 days) and the clinical outcome assessed monthly."	1.42	Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. ( Avishek, K; Deep, DK; Ramesh, V; Salotra, P; Singh, R; Verma, A; Verma, S, 2015)
" Initial dose-response experiments showed that an oral daily dose of 40 mg/kg of OlPC was needed to impact time to cure and lesion sizes."	1.40	Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis. ( Bosschaerts, T; Caridha, DP; Fortin, A; Grogl, M; Hickman, MR; Hudson, TH; Leed, S; Ngundam, F; Parriott, S; Sena, J, 2014)
"Treatment with meglumine antimoniate had to be interrupted in six patients, with QTc prolongation the reason for the interruption in three patients."	1.39	Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment. ( Blum, JA; Hatz, C; Mosimann, V; Neumayr, A, 2013)
"Miltefosine is an alkylphospholipid analogue that exhibits potent activity against the different clinical manifestations of leishmaniasis."	1.38	Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice. ( de Souza, W; Godinho, JL; Rodrigues, JC; Silva, R; Simas-Rodrigues, C; Ürmenyi, TP, 2012)
"Miltefosine treatment cured two patients with L."	1.37	A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis. ( Fedorko, DP; Mahanty, S; Nash, TE; Ramanathan, R; Talaat, KR, 2011)
" These observations illustrate the usability of quantifying parasite loads in skin lesions as a pharmacodynamic measure and quantitative descriptor of drug effect for CL supporting clinical assessment."	1.37	Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. ( Beijnen, JH; de Vries, PJ; Dorlo, TP; Schoone, GJ; Stienstra, Y; van Thiel, PP; van Vugt, M, 2011)
"Miltefosine treatment did not influence DC maturation (upregulation of major histocompatibility complex II [MHC II] or costimulatory molecules, e."	1.36	Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions. ( Eichhorn, A; Gazeau, C; Griewank, K; von Stebut, E, 2010)
"Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas."	1.36	Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010)
"Miltefosine has been established as the first oral administration drug against cutaneous and visceral leishmaniasis."	1.35	In vivo activity of perifosine against Leishmania amazonensis. ( Cabrera-Serra, MG; Piñero, JE; Valladares, B, 2008)
"Mucocutaneous leishmaniasis is a serious preventable complication of cutaneous leishmaniasis."	1.35	[Mucosal complication of cutaneous leishmaniasis]. ( Figueroa, RA; Miranda, MC; Prager, M; Zea, DF, 2009)
"Miltefosine was administered orally at 25 mg/kg/day for 10 days, while 10% paromomycin gel was applied topically twice a day for 10 days."	1.35	Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. ( Aguiar, MG; Fernandes, AP; Ferreira, LA; Nunan, EA; Nunan, FA; Silva, DL, 2009)
"Miltefosine is a less toxic option to replace the antimony compounds."	1.34	[Cutaneous leishmaniasis]. ( Sunderkötter, C; von Stebut, E, 2007)
"Miltefosine was given 100mg daily in divided doses for an initial 8 weeks."	1.33	Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. ( Agrawal, D; Agrawal, S; Chakravarty, J; Chhabra, A; Kumar, K; Singh, V; Sundar, S, 2006)

Research

Studies (170)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Complete Clinical Response

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	47 (27.65)	29.6817
2010's	87 (51.18)	24.3611
2020's	36 (21.18)	2.80

Authors	Studies
Dorlo, TP	3
van Thiel, PP	4
Huitema, AD	1
Keizer, RJ	1
de Vries, HJ	5
Beijnen, JH	4
de Vries, PJ	6
Griewank, K	1
Gazeau, C	1
Eichhorn, A	1
von Stebut, E	2
Stroppa, PHF	2
Antinarelli, LMR	1
Carmo, AML	1
Gameiro, J	1
Coimbra, ES	2
da Silva, AD	2
Temraz, MG	1
Elzahhar, PA	1
El-Din A Bekhit, A	1
Bekhit, AA	1
Labib, HF	1
Belal, ASF	1
Emiliano, YSS	1
Almeida-Amaral, EE	1
Monge-Maillo, B	2
Norman, FF	1
Chamorro-Tojeiro, S	1
Gioia, F	1
Pérez-Molina, JA	1
Chicharro, C	1
Moreno, J	1
López-Vélez, R	4
López, L	3
Valencia, B	1
Alvarez, F	1
Ramos, AP	1
Llanos-Cuentas, A	2
Echevarria, J	1
Vélez, I	2
Boni, M	1
Rode, J	1
Quintero, J	1
Jiménez, A	1
Tabares, Y	1
Méndez, C	1
Arana, B	3
Barba, PJ	1
Morgado-Carrasco, D	1
Quera, A	1
Bano, S	3
Bibi, M	4
Farooq, S	3
Zafar, H	3
Shaikh, M	3
Khoso, BK	3
Yousuf, S	3
Choudhary, MI	3
Ferreira, BA	1
Coser, EM	1
Saborito, C	1
Yamashiro-Kanashiro, EH	1
Lindoso, JAL	1
Coelho, AC	5
Van Bocxlaer, K	3
Dixon, J	1
Platteeuw, JJ	1
Van Den Heuvel, D	1
Mcarthur, KN	1
Harris, A	1
Alavijeh, M	1
Croft, SL	6
Yardley, V	5
Carregal, VM	1
Lanza, JS	1
Souza, DM	1
Islam, A	1
Demicheli, C	1
Fujiwara, RT	1
Rivas, L	1
Frézard, F	2
Meinel, RS	1
Almeida, ADC	1
Glanzmann, N	1
Dar, MJ	2
Khalid, S	1
McElroy, CA	1
Satoskar, AR	1
Khan, GM	3
Ramesh, V	8
Dixit, KK	1
Sharma, N	1
Singh, R	2
Salotra, P	8
Topno, RK	4
Rabi Das, VN	1
Kumar, M	1
Madhukar, M	1
Pandey, K	5
Verma, N	4
Agrawal, K	1
Lal, CS	4
Siddiqui, NA	2
Bimal, S	3
Das, P	5
Özbilgin, A	2
Çavuş, İ	2
Kaya, T	1
Yıldırım, A	1
Harman, M	2
Mann, S	1
Phupitakphol, T	1
Davis, B	1
Newman, S	1
Suarez, JA	1
Henao-Martínez, A	1
Franco-Paredes, C	1
Kabra, R	1
Ingale, P	1
Singh, S	1
Peixoto, F	1
Nascimento, MT	1
Costa, R	1
Silva, J	1
Renard, G	1
Guimarães, LH	3
Penna, G	4
Barral-Netto, M	3
Carvalho, LP	1
Machado, PRL	3
Carvalho, EM	5
Pinart, M	1
Rueda, JR	1
Romero, GA	1
Pinzón-Flórez, CE	1
Osorio-Arango, K	1
Silveira Maia-Elkhoury, AN	1
Reveiz, L	1
Elias, VM	1
Tweed, JA	1
Prates, FVO	1
Boaventura, V	1
Lago, T	1
Schriefer, A	3
Corte, TWF	1
Barral, A	1
Kusumesh, R	1
Ambasta, A	1
Arya, LK	1
Mohan, N	1
Sinha, BP	1
Ravidas, V	1
Tunalı, V	1
Gündüz, C	1
Turgay, N	1
Ollech, A	2
Solomon, M	2
Horev, A	2
Reiss-Huss, S	2
Ben-Amitai, D	2
Zvulunov, A	2
Friedland, R	2
Atar-Snir, V	2
Molho-Pessach, V	1
Barzilai, A	2
Greenberger, S	2
Ware, JM	1
O'Connell, EM	1
Brown, T	1
Wetzler, L	1
Talaat, KR	2
Nutman, TB	1
Nash, TE	2
Soto, JA	1
Berman, JD	3
Chan, CX	1
Simmons, BJ	1
Call, JE	1
Yan, S	1
Glass, JS	1
Chapman, MS	1
Pessach-Molcho, V	1
Parajuli, N	1
Adhikary, S	1
Karki, A	1
Tiwari, S	1
Khan, AS	1
Ud Din, F	1
Ali, Z	1
Zahid, F	2
Zeb, A	2
Mendes, L	1
Guerra, JO	1
Costa, B	1
Silva, ASD	1
Guerra, MDGB	1
Ortiz, J	1
Doria, SS	1
Silva, GVD	1
de Jesus, DV	1
Pal, B	2
Das, VNR	2
Peralta, MF	1
Usseglio, NA	1
Bracamonte, ME	1
Guzmán, ML	1
Olivera, ME	1
Marco, JD	1
Barroso, PA	1
Carrer, DC	1
Kämink, S	1
Masih, B	1
Ali, N	1
Ullah, A	1
Khan, SJ	1
Ashraf, S	1
Pylypenko, T	1
Grobusch, MP	1
Fernhout, J	1
den Boer, M	1
Ritmeijer, K	3
Batool, S	1
Ud-Din, F	1
Naz, SS	1
Khan, MW	1
Tayyebi, M	1
Darchini-Maragheh, E	1
Layegh, P	1
Kiafar, B	1
Goyonlo, VM	1
Zhao, YL	1
Li, SH	1
Zhu, X	1
Zhou, RM	1
Yang, CY	1
Liu, Y	1
Niu, YN	1
Lu, L	1
Zhang, HW	1
Zhao, DY	1
Nepal, S	1
Joseph, S	1
Whitman, TJ	1
Buckner, FS	1
Cogen, AL	1
van Henten, S	1
Tesfaye, AB	1
Abdela, SG	1
Tilahun, F	1
Fikre, H	1
Buyze, J	1
Kassa, M	1
Cnops, L	2
Pareyn, M	1
Mohammed, R	1
Vogt, F	1
Diro, E	1
van Griensven, J	1
Martins, SS	1
Barroso, DH	1
Rodrigues, BC	1
da Motta, JOC	1
Freire, GSM	1
Pereira, LIA	1
Kurisky, PS	1
Gomes, CM	1
Sampaio, RNR	2
Castro, MDM	4
Cossio, A	4
Velasco, C	1
Osorio, L	2
Berger, BA	1
Saravia, NG	3
Prada, S	1
Bartlett, AH	1
Pho, MT	1
Wijnant, GJ	1
Murdan, S	2
Darcis, G	1
Van der Auwera, G	1
Giot, JB	1
Hayette, MP	1
Tassin, F	1
Arrese Estrada, J	1
Moutschen, M	1
de Leval, L	1
Leonard, P	1
Medina-Morales, DA	1
Machado-Duque, ME	1
Machado-Alba, JE	1
Moulik, S	1
Chaudhuri, SJ	1
Sardar, B	1
Ghosh, M	1
Saha, B	2
Das, NK	4
Chatterjee, M	6
Pradhan, A	1
Basak, S	1
Chowdhury, T	1
Mohanta, A	1
Chatterjee, A	1
Nieto-Meneses, R	1
Castillo, R	1
Hernández-Campos, A	1
Maldonado-Rangel, A	1
Matius-Ruiz, JB	1
Trejo-Soto, PJ	1
Nogueda-Torres, B	1
Dea-Ayuela, MA	1
Bolás-Fernández, F	1
Méndez-Cuesta, C	1
Yépez-Mulia, L	1
Almustafa, ZZ	1
Sasama, B	1
Peitsch, WK	1
Ponte-Sucre, A	1
Gamarro, F	1
Dujardin, JC	3
Barrett, MP	1
García-Hernández, R	1
Pountain, AW	1
Mwenechanya, R	1
Papadopoulou, B	1
Hamzavi, SS	1
Sanaei Dashti, A	1
Kadivar, MR	2
Pouladfar, G	1
Pourabbas, B	1
Dhorm Pimentel de Moraes, AR	1
Tavares, GD	1
Soares Rocha, FJ	1
de Paula, E	1
Giorgio, S	1
Nazari-Vanani, R	1
Vais, RD	1
Sharifi, F	1
Sattarahmady, N	1
Karimian, K	1
Motazedian, MH	2
Heli, H	1
Kip, AE	1
Gomez, MA	3
Schellens, JHM	1
Dorlo, TPC	1
Hossain, MS	2
Kumar, A	1
Hossain, AFMA	1
Mahshin, M	1
Sharma, A	1
Hossain, MA	1
Sharma, V	2
Haque, R	2
Shamsuzzaman, AKM	1
Maruf, S	2
Ghosh, P	3
Ahuja, V	1
Mondal, D	5
Nath, P	2
Islam, MR	1
Aktar, F	1
Anuwarul, A	1
Basher, A	2
Prieto, MD	1
Uribe-Restrepo, AF	1
Arcos, D	1
Vargas, DA	1
New, D	1
Rogers, BA	1
Uribe-Restrepo, A	1
Desai, MM	1
Dávalos, D	1
Guerveno, C	1
Delavigne, K	1
Berry, A	1
Martin-Blondel, G	1
Delobel, P	1
Regli, IB	1
Fernández, OL	2
Martínez-Salazar, B	1
Tacchini-Cottier, F	1
Carvalho, SH	1
Pereira, NP	1
Moura, AS	1
Ramos, LMQC	1
Carvalho, GB	1
Rocha, MOC	1
Leañez, J	1
Nuñez, J	1
García-Marchan, Y	1
Sojo, F	1
Arvelo, F	1
Rodriguez, D	1
Buscema, I	1
Alvarez-Aular, A	1
Bello Forero, JS	1
Kouznetsov, VV	1
Serrano-Martín, X	2
Pijpers, J	1
den Boer, ML	1
Essink, DR	1
Abongomera, C	1
Battaglioli, T	1
Adera, C	1
Neira, LF	1
Mantilla, JC	1
Escobar, P	1
Espada, CR	2
Magalhães, RM	1
Cruz, MC	1
Machado, PR	2
Hornillos, V	1
Alves, JM	1
Cruz, AK	1
Uliana, SRB	1
Iranpour, S	1
Hosseinzadeh, A	1
Alipour, A	1
Cavalcanti de Queiroz, A	1
Alves, MA	1
Barreiro, EJ	1
Lima, LM	1
Alexandre-Moreira, MS	1
Rashid, MM	1
Habibullah, AM	1
Nath, R	2
Akter, D	1
Chowdhury, IH	1
Azim, A	1
Faiz, MA	1
Kavian, Z	1
Alavizadeh, SH	1
Golmohamadzadeh, S	1
Badiee, A	1
Khamesipour, A	2
Jaafari, MR	1
Utaile, M	1
Kassahun, A	1
Abebe, T	1
Hailu, A	1
Eichner, S	1
Thoma-Uszynski, S	1
Herrgott, I	1
Sebald, H	1
Debus, A	1
Tsianakas, A	1
Ehrchen, J	1
Harms, G	2
Simon, M	1
Sunderkötter, C	2
Bogdan, C	1
Cruz, C	1
Godoy, G	1
Robledo, SM	1
Vélez, ID	1
Mosimann, V	1
Neumayr, A	1
Hatz, C	1
Blum, JA	1
Salam, MA	1
Siddiqui, MA	1
Nabi, SG	1
Bhaskar, KR	1
Avishek, K	2
Obonaga, R	1
Valderrama, L	1
Rubiano, LC	2
Castro, Mdel M	1
Barrera, MC	1
Gore Saravia, N	2
Dieterle, R	1
Pillekamp, H	1
García Bustos, MF	1
Barrio, A	1
Prieto, GG	1
de Raspi, EM	1
Cimino, RO	1
Cardozo, RM	1
Parada, LA	1
Yeo, M	1
Soto, J	6
Uncos, DA	1
Parodi, C	1
Basombrío, MA	1
Fortin, A	1
Caridha, DP	1
Leed, S	1
Ngundam, F	1
Sena, J	1
Bosschaerts, T	1
Parriott, S	1
Hickman, MR	1
Hudson, TH	1
Grogl, M	1
Santarem, AA	1
Greggianin, GF	1
Debastiani, RG	1
Ribeiro, JB	1
Polli, DA	1
Sampaio, RN	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.[NCT01462500]	Phase 4	60 participants (Actual)	Interventional	2011-10-31	Completed
A Randomized, Open Label, Multicenter Study to Determine the Efficacy and Safety of Combining Thermotherapy and a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨[NCT02687971]	Phase 2	130 participants (Actual)	Interventional	2016-12-31	Completed
Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial[NCT03023111]	Phase 3	300 participants (Actual)	Interventional	2017-06-30	Completed
Documenting Clinical Outcomes of Patients Receiving Miltefosine for the Treatment of Complicated Cutaneous Leishmaniasis in Ethiopia[NCT04004754]		94 participants (Actual)	Observational	2019-05-07	Completed
Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia[NCT00487253]	Phase 3	150 participants (Anticipated)	Interventional	2007-07-31	Active, not recruiting
Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis[NCT01464242]	Phase 2/Phase 3	75 participants (Actual)	Interventional	2011-11-30	Completed
Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705]	Phase 3	437 participants (Actual)	Interventional	2006-06-30	Completed
A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL[NCT02193022]	Phase 3	80 participants (Actual)	Interventional	2014-07-31	Completed
Evaluation of the Safety and Clinical Activity of Curaleish Lotion and Cream in the Topical Treatment of Cutaneous Leishmaniasis in Colombia[NCT04072874]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2021-01-31	Withdrawn (stopped due to Tthe study is in the approval phase by local regulatory authorities)
Randomized Clinical Trial to Evaluate the Safety and Therapeutic Response of Two ARNICA TINCTURE Treatment Regimes in the Topical Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia[NCT05094908]	Phase 1	16 participants (Anticipated)	Interventional	2023-05-03	Recruiting
Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control[NCT00600548]	Phase 2	180 participants (Actual)	Interventional	2007-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment

Failure

Intervention	participants (Number)
Miltefosine	85
Glucantime®	103
Thermotherapy	86

At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment

Recurrence

Intervention	participants (Number)
Miltefosine	34
Glucantime®	14
Thermotherapy	42

Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment

Article	Year
Interventions for American cutaneous and mucocutaneous leishmaniasis. The Cochrane database of systematic reviews, 2020, 08-27, Volume: 8 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Azithromycin; BCG Vaccine; Female; Humans; Hypert	2020
Keratitis After Post-Kala-Azar Dermal Leishmaniasis. Cornea, 2018, Volume: 37, Issue:1 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Corneal Stroma; Eye Infections, Parasitic; Glucoc	2018
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:12 Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Drug Therapy, Combination; Humans; Leishmania	2017
Interventions to treat cutaneous leishmaniasis in children: A systematic review. PLoS neglected tropical diseases, 2018, Volume: 12, Issue:12 Topics: Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglum	2018
American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment. Tropical medicine & international health : TM & IH, 2019, Volume: 24, Issue:4 Topics: Antiprotozoal Agents; Brazil; Humans; Leishmania braziliensis; Leishmania guyanensis; Leishmaniasis,	2019
The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis. PLoS neglected tropical diseases, 2019, Volume: 13, Issue:2 Topics: Antiprotozoal Agents; Asia; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcho	2019
Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis. Epidemiology and health, 2019, Volume: 41 Topics: Humans; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Non-Randomized Controlled Trials as Topic;	2019
Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic. The British journal of dermatology, 2015, Volume: 172, Issue:4 Topics: Administration, Cutaneous; Ambulatory Care; Aminoglycosides; Antiprotozoal Agents; Child, Preschool;	2015
Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, May-01, Volume: 60, Issue:9 Topics: Administration, Oral; Africa, Eastern; Antiprotozoal Agents; Bangladesh; Coinfection; Drug Therapy,	2015
Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. Pharmacotherapy, 2015, Volume: 35, Issue:5 Topics: Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasi	2015
Treatment of leishmaniasis with miltefosine: 2008 status. Expert opinion on drug metabolism & toxicology, 2008, Volume: 4, Issue:9 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Female; Humans;	2008
Drug delivery systems for the topical treatment of cutaneous leishmaniasis. Expert opinion on drug delivery, 2012, Volume: 9, Issue:9 Topics: Administration, Cutaneous; Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Deli	2012
Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine. The Journal of the Association of Physicians of India, 2003, Volume: 51 Topics: Administration, Oral; Aminoquinolines; Animals; Antiprotozoal Agents; Clinical Trials as Topic; Dose	2003
Cutaneous leishmaniasis: current and future management. Expert review of anti-infective therapy, 2003, Volume: 1, Issue:4 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Humans; Immunotherapy; Leishmania; Leishmaniasis	2003
Miltefosine to treat leishmaniasis. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:8 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis	2005
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish	2006
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish	2006
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish	2006
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish	2006
Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100 Suppl 1 Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Drug Design; Glycerylphosphorylcholine; Leishm	2006
Treatment of New World cutaneous leishmaniasis with miltefosine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100 Suppl 1 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Clinical Trials as Topic; Double-Blind Method; Dr	2006
[Miltefosine: a new remedy for leishmaniasis]. Nederlands tijdschrift voor geneeskunde, 2006, Dec-09, Volume: 150, Issue:49 Topics: Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphoryl	2006
Cutaneous leishmaniasis treatment. Travel medicine and infectious disease, 2007, Volume: 5, Issue:3 Topics: Administration, Cutaneous; Administration, Oral; Aminoquinolines; Amphotericin B; Animals; Antimony;	2007
Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. The British journal of dermatology, 2007, Volume: 157, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Americas; Antiprotozoal Agents; Antiretroviral Therapy, Highly A	2007
Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. Medical microbiology and immunology, 2001, Volume: 190, Issue:1-2 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Child, Preschool; Clinical Trials as Topic	2001
Chemotherapy of cutaneous leishmaniasis: a review. Medical microbiology and immunology, 2001, Volume: 190, Issue:1-2 Topics: Antifungal Agents; Antimony; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Ointments;	2001

Article	Year
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:8 Topics: Adult; Afghanistan; Animals; Antiprotozoal Agents; Chromatography, Liquid; Female; Humans; Leishmani	2008
A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World. PLoS neglected tropical diseases, 2022, Volume: 16, Issue:3 Topics: Adult; Antiprotozoal Agents; Humans; Hyperthermia, Induced; Leishmaniasis, Cutaneous; Meglumine; Meg	2022
A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 10-05, Volume: 73, Issue:7 Topics: Antimony; Antiprotozoal Agents; Brazil; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocyt	2021
Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 103 Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Antiprotozoal Agents; Female; Gran	2021
A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis. Frontiers in cellular and infection microbiology, 2021, Volume: 11 Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Pentoxifylline; Phosphorylcholine; Pilot Pro	2021
Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8 Topics: Adult; Child; Child, Preschool; Colombia; Dose-Response Relationship, Drug; Female; Humans; Leishman	2018
Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. Revista do Instituto de Medicina Tropical de Sao Paulo, 2013, Volume: 55, Issue:3 Topics: Adult; Antiprotozoal Agents; Colombia; Follow-Up Studies; Humans; Hyperthermia, Induced; Leishmanias	2013
[Cutaneous leishmaniasis. Diagnosis and therapy in northern Afghanistan]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2014, Volume: 65, Issue:2 Topics: Administration, Topical; Adult; Afghanistan; Antimony Sodium Gluconate; Antiprotozoal Agents; Combin	2014
Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. TheScientificWorldJournal, 2015, Volume: 2015 Topics: Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosp	2015
Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis. The American journal of tropical medicine and hygiene, 2015, Volume: 93, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Drug Administration Schedule; Female; Humans; Leishm	2015
Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study. The British journal of dermatology, 2017, Volume: 177, Issue:2 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Drug Administration Schedule; Drug Therapy, Combi	2017
Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Veterinary dermatology, 2009, Volume: 20, Issue:5-6 Topics: Allopurinol; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis, Cutaneou	2009
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:2 Topics: Adult; Antiprotozoal Agents; Capsules; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis,	2010
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:2 Topics: Adult; Antiprotozoal Agents; Capsules; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis,	2010
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:2 Topics: Adult; Antiprotozoal Agents; Capsules; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis,	2010
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:2 Topics: Adult; Antiprotozoal Agents; Capsules; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis,	2010
Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment. The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:6 Topics: Adult; Afghanistan; Antiprotozoal Agents; Cryotherapy; Humans; Leishmania major; Leishmaniasis, Cuta	2010
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS neglected tropical diseases, 2010, Dec-21, Volume: 4, Issue:12 Topics: Abdominal Pain; Administration, Oral; Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Brazi	2010
Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. The Journal of infectious diseases, 2012, Feb-15, Volume: 205, Issue:4 Topics: Administration, Oral; Antiprotozoal Agents; Child; Child, Preschool; Colombia; Female; Humans; Leish	2012
Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Tropical medicine & international health : TM & IH, 2013, Volume: 18, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Female; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous	2013
Miltefosine for new world cutaneous leishmaniasis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, May-01, Volume: 38, Issue:9 Topics: Administration, Oral; Adult; Animals; Antiprotozoal Agents; Colombia; Double-Blind Method; Drug Tole	2004
Oral miltefosine to treat new world cutaneous leishmaniasis. The Lancet. Infectious diseases, 2007, Volume: 7, Issue:1 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis,	2007
Miltefosine in cutaneous leishmaniasis. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2007, Volume: 17, Issue:3 Topics: Adult; Antimony; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Me	2007
Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta tropica, 2007, Volume: 103, Issue:1 Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Female; Humans; Iran; Leishmaniasis, Cutaneous; Ma	2007
Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. The American journal of tropical medicine and hygiene, 2008, Volume: 78, Issue:2 Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Bolivia; Child; Female; Humans; Leishmania brazili	2008
Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. The American journal of tropical medicine and hygiene, 2008, Volume: 78, Issue:2 Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Bolivia; Child; Female; Humans; Leishmania brazili	2008
Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. The American journal of tropical medicine and hygiene, 2008, Volume: 78, Issue:2 Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Bolivia; Child; Female; Humans; Leishmania brazili	2008
Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. The American journal of tropical medicine and hygiene, 2008, Volume: 78, Issue:2 Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Bolivia; Child; Female; Humans; Leishmania brazili	2008
Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Oct-01, Volume: 33, Issue:7 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Colombia; Humans; Leishmaniasis, Cutaneous; Male;	2001

Article	Year
Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2 Topics: Animals; Antiprotozoal Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Ce	2010
Effect of 1,2,3-triazole salts, non-classical bioisosteres of miltefosine, on Leishmania amazonensis. Bioorganic & medicinal chemistry, 2017, 06-15, Volume: 25, Issue:12 Topics: Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Erythrocytes; Humans; Leishmania mexicana; Leis	2017
Anti-leishmanial click modifiable thiosemicarbazones: Design, synthesis, biological evaluation and in silico studies. European journal of medicinal chemistry, 2018, May-10, Volume: 151 Topics: Animals; Chlorocebus aethiops; Click Chemistry; Drug Design; Humans; Leishmania major; Leishmaniasis	2018
Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis. Journal of natural products, 2018, 08-24, Volume: 81, Issue:8 Topics: Animals; Antiprotozoal Agents; Apigenin; Biomarkers; Drug Combinations; Female; Leishmania mexicana;	2018
Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine. Journal of travel medicine, 2022, 11-04, Volume: 29, Issue:7 Topics: Antiprotozoal Agents; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Cutaneous; Leishma	2022
Miltefosine to Treat Childhood Cutaneous Leishmaniasis. Actas dermo-sifiliograficas, 2022, Volume: 113, Issue:8 Topics: Antiprotozoal Agents; Child; Humans; Leishmaniasis, Cutaneous; Phosphorylcholine	2022
Anti-leishmanial physalins-Phytochemical investigation, in vitro evaluation against clinical and MIL-resistant L. tropica strains and in silico studies. PloS one, 2022, Volume: 17, Issue:11 Topics: Antiprotozoal Agents; Humans; Leishmania major; Leishmaniasis, Cutaneous; Molecular Docking Simulati	2022
Anti-leishmanial physalins-Phytochemical investigation, in vitro evaluation against clinical and MIL-resistant L. tropica strains and in silico studies. PloS one, 2022, Volume: 17, Issue:11 Topics: Antiprotozoal Agents; Humans; Leishmania major; Leishmaniasis, Cutaneous; Molecular Docking Simulati	2022
Anti-leishmanial physalins-Phytochemical investigation, in vitro evaluation against clinical and MIL-resistant L. tropica strains and in silico studies. PloS one, 2022, Volume: 17, Issue:11 Topics: Antiprotozoal Agents; Humans; Leishmania major; Leishmaniasis, Cutaneous; Molecular Docking Simulati	2022
Anti-leishmanial physalins-Phytochemical investigation, in vitro evaluation against clinical and MIL-resistant L. tropica strains and in silico studies. PloS one, 2022, Volume: 17, Issue:11 Topics: Antiprotozoal Agents; Humans; Leishmania major; Leishmaniasis, Cutaneous; Molecular Docking Simulati	2022
In vitro miltefosine and amphotericin B susceptibility of strains and clinical isolates of Leishmania species endemic in Brazil that cause tegumentary leishmaniasis. Experimental parasitology, 2023, Volume: 246 Topics: Amphotericin B; Antiprotozoal Agents; Brazil; Humans; Leishmania; Leishmaniasis; Leishmaniasis, Cuta	2023
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis. The Journal of antimicrobial chemotherapy, 2023, 07-05, Volume: 78, Issue:7 Topics: Animals; Antiprotozoal Agents; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral;	2023
Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine. Parasitology research, 2019, Volume: 118, Issue:10 Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Female; Leish	2019
Novel functionalized 1,2,3-triazole derivatives exhibit antileishmanial activity, increase in total and mitochondrial-ROS and depolarization of mitochondrial membrane potential of Leishmania amazonensis. Chemico-biological interactions, 2020, Jan-05, Volume: 315 Topics: Animals; Antiprotozoal Agents; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages, Peritonea	2020
Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes. International journal of pharmaceutics, 2020, Jan-05, Volume: 573 Topics: Administration, Cutaneous; Amphotericin B; Animals; Antiprotozoal Agents; Disease Models, Animal; Dr	2020
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis. The Journal of infectious diseases, 2020, 02-03, Volume: 221, Issue:4 Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; DNA, Protozoan; Drug Therapy, Combin	2020
Advanced case of PKDL due to delayed treatment: A rare case report. PLoS neglected tropical diseases, 2020, Volume: 14, Issue:3 Topics: Antiprotozoal Agents; Humans; India; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, V	2020
Comparison of Turkiye parazitolojii dergisi, 2020, Mar-20, Volume: 44, Issue:1 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Female; G	2020
Case Report: Cutaneous Leishmaniasis due to The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:3 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Biopsy; Central America; Female; Humans; Leishman	2020
Computationally designed synthetic peptides for transporter proteins imparts allostericity in Miltefosine resistant L. major. The Biochemical journal, 2020, 05-29, Volume: 477, Issue:10 Topics: Allosteric Regulation; Animals; Antiprotozoal Agents; ATP Binding Cassette Transporter, Subfamily B,	2020
Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis. Journal of immunology research, 2020, Volume: 2020 Topics: Administration, Topical; Antiprotozoal Agents; Cytokines; Cytotoxicity, Immunologic; Female; Granulo	2020
Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis. The British journal of ophthalmology, 2021, Volume: 105, Issue:11 Topics: Adolescent; Adult; Antiprotozoal Agents; Female; Glucocorticoids; Humans; Keratitis; Leishmaniasis,	2021
Overcoming the Challenge; In Vivo Efficacy of Miltefosine for Chronic Cutaneous Leishmaniasis. Acta parasitologica, 2021, Volume: 66, Issue:2 Topics: Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Mice;	2021
Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients. Acta dermato-venereologica, 2020, 10-19, Volume: 100, Issue:18 Topics: Adolescent; Antiprotozoal Agents; Child; Child, Preschool; Humans; Israel; Leishmaniasis, Cutaneous;	2020
Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 10-05, Volume: 73, Issue:7 Topics: Antiprotozoal Agents; Humans; Leishmania infantum; Leishmaniasis, Cutaneous; Phosphorylcholine	2021
Miltefosine Treatment of Cutaneous Leishmaniasis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 10-05, Volume: 73, Issue:7 Topics: Humans; Leishmaniasis, Cutaneous; Phosphorylcholine	2021
Cutaneous leishmaniasis successfully treated with miltefosine. Cutis, 2020, Volume: 106, Issue:4 Topics: Adult; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Male; Middle Aged; Phosphoryl	2020
Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients. Acta dermato-venereologica, 2020, 11-18, Volume: 100, Issue:18 Topics: Adolescent; Antiprotozoal Agents; Child; Child, Preschool; Humans; Israel; Leishmaniasis, Cutaneous;	2020
Case Report: Erysipeloid Cutaneous Leishmaniasis Treated with Oral Miltefosine. The American journal of tropical medicine and hygiene, 2020, 11-23, Volume: 104, Issue:2 Topics: Administration, Oral; Aged; Antibodies, Protozoan; Antiprotozoal Agents; Erysipeloid; Humans; Leishm	2020
Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of Cutaneous Leishmaniasis. International journal of pharmaceutics, 2021, Jan-25, Volume: 593 Topics: Drug Carriers; Humans; Leishmaniasis, Cutaneous; Lipids; Nanostructures; Particle Size; Phosphorylch	2021
Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical, 2020, Volume: 54 Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine;	2020
Efficacy of topical Miltefosine formulations in an experimental model of cutaneous leishmaniasis. Drug delivery and translational research, 2022, Volume: 12, Issue:1 Topics: Animals; Leishmania; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Models, Theoretical; Phosp	2022
Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy-A retrospective analysis. PLoS neglected tropical diseases, 2021, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Child; Female; Humans; Leishmania tropica;	2021
Macrophage targeting with the novel carbopol-based miltefosine-loaded transfersomal gel for the treatment of cutaneous leishmaniasis: Drug development and industrial pharmacy, 2021, Volume: 47, Issue:3 Topics: Acrylic Resins; Animals; Leishmaniasis, Cutaneous; Macrophages; Mice; Mice, Inbred BALB C; Phosphory	2021
The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial. PLoS neglected tropical diseases, 2021, Volume: 15, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resista	2021
Investigating the Aggregation of Imported Cutaneous Leishmaniasis in Henan, Central China. Biomedical and environmental sciences : BES, 2021, Mar-20, Volume: 34, Issue:3 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; China; Communicable Diseas	2021
Case Report: An Atypical Erysipeloid Presentation of Cutaneous Leishmaniasis from the Hilly Region of Nepal. The American journal of tropical medicine and hygiene, 2021, 05-10, Volume: 105, Issue:1 Topics: Antifungal Agents; Antiprotozoal Agents; Fluconazole; Humans; Leishmaniasis, Cutaneous; Male; Middle	2021
Case Report: Miltefosine Failure and Spontaneous Resolution of Cutaneous Leishmaniasis braziliensis. The American journal of tropical medicine and hygiene, 2021, 05-10, Volume: 105, Issue:1 Topics: Antiprotozoal Agents; Female; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Peru; Phosp	2021
Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia. PLoS neglected tropical diseases, 2021, Volume: 15, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Cohort Studies; Ethiopia; Female; Hum	2021
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female;	2017
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female;	2017
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female;	2017
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female;	2017
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female;	2017
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female;	2017
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female;	2017
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female;	2017
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female;	2017
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:4 Topics: Administration, Oral; Antiprotozoal Agents; Caregivers; Child; Child, Preschool; Cost-Benefit Analys	2017
Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:8 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Chloroquine; Disease Models, Animal; Drug Combination	2017
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. BMC infectious diseases, 2017, 07-07, Volume: 17, Issue:1 Topics: Amphotericin B; Antiprotozoal Agents; Biopsy; Female; Humans; Immunocompromised Host; Leishmania; Le	2017
Epidemiology of Cutaneous Leishmaniasis in a Colombian Municipality. The American journal of tropical medicine and hygiene, 2017, Volume: 97, Issue:5 Topics: Adolescent; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Colombia; Fema	2017
Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 01-18, Volume: 66, Issue:3 Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Asymptomatic Infections; Biopsy; DNA, Inter	2018
In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species. Experimental parasitology, 2018, Volume: 184 Topics: Amino Acid Sequence; Amphotericin B; Animals; Antiprotozoal Agents; Arginase; Benzimidazoles; Cell L	2018
Perichondritis of the ear in an Afghan immigrant. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2018, Volume: 16, Issue:4 Topics: Adult; Afghanistan; Animals; Biopsy; Cartilage Diseases; Diagnosis, Differential; Ear Diseases; Ear,	2018
Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl. The Pediatric infectious disease journal, 2018, Volume: 37, Issue:3 Topics: Amphotericin B; Antiprotozoal Agents; Child; Female; Humans; Iran; Leishmaniasis, Cutaneous; Phospho	2018
Effects of nanoemulsions prepared with essential oils of copaiba- and andiroba against Leishmania infantum and Leishmania amazonensis infections. Experimental parasitology, 2018, Volume: 187 Topics: Animals; Antiprotozoal Agents; Emulsions; Fabaceae; Female; Gas Chromatography-Mass Spectrometry; In	2018
Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes. Acta tropica, 2018, Volume: 185 Topics: Animals; Antiprotozoal Agents; Ketoconazole; Leishmania major; Leishmaniasis, Cutaneous; Nanostructu	2018
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Infectious diseases of poverty, 2018, Aug-13, Volume: 7, Issue:1 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Bangladesh; Fema	2018
Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment. PLoS neglected tropical diseases, 2018, Volume: 12, Issue:9 Topics: Adolescent; Adult; Antiprotozoal Agents; Bangladesh; Humans; Keratitis; Leishmaniasis, Cutaneous; Le	2018
Case Report: Squamous Cell Carcinoma Referred for Mohs Surgery Found to be Cutaneous Leishmaniasis. The American journal of tropical medicine and hygiene, 2018, Volume: 99, Issue:6 Topics: Antibodies, Protozoan; Antiprotozoal Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Fema	2018
Case Reports: Late Emergence of Cutaneous Leishmaniasis in an Immunocompromised Patient in a Non-Endemic Setting. The American journal of tropical medicine and hygiene, 2019, Volume: 100, Issue:1 Topics: Adult; Afghanistan; Antiprotozoal Agents; Australia; Biopsy; DNA, Ribosomal Spacer; Humans; Immunoco	2019
[Refractory cutaneous leishmaniasis: Benefit of miltefosine]. Medecine et maladies infectieuses, 2019, Volume: 49, Issue:4 Topics: Aged; Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis, Cutaneous; Male; Phosphorylcholi	2019
Resistance of Frontiers in immunology, 2018, Volume: 9 Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Drug Resistance; Extracellular Traps; Humans; Leishm	2018
Anti-leishmanial effect of spiro dihydroquinoline-oxindoles on volume regulation decrease and sterol biosynthesis of Leishmania braziliensis. Experimental parasitology, 2019, Volume: 198 Topics: Animals; Antiprotozoal Agents; Inhibitory Concentration 50; Leishmania braziliensis; Leishmaniasis,	2019
Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2019, Volume: 81 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Ethiopia; HIV Infections; Humans; Leishmania dono	2019
Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis. The Journal of antimicrobial chemotherapy, 2019, 06-01, Volume: 74, Issue:6 Topics: Administration, Topical; Animals; Antiprotozoal Agents; Biopsy; Disease Models, Animal; Drug Stabili	2019
Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake. International journal for parasitology. Drugs and drug resistance, 2019, Volume: 11 Topics: Biological Transport; Drug Resistance; Gene Expression Profiling; Humans; Leishmania braziliensis; L	2019
Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis. Experimental parasitology, 2019, Volume: 201 Topics: Analysis of Variance; Animals; Antiprotozoal Agents; Caspases; Cell Cycle; Cell Line; Cell Membrane;	2019
Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh. Mymensingh medical journal : MMJ, 2019, Volume: 28, Issue:2 Topics: Adolescent; Antiprotozoal Agents; Bangladesh; Fertility; Humans; Infertility, Male; Leishmaniasis, C	2019
Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice. Acta tropica, 2019, Volume: 196 Topics: Administration, Topical; Animals; Antiprotozoal Agents; Leishmania major; Leishmaniasis, Cutaneous;	2019
Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model. Experimental parasitology, 2013, Volume: 134, Issue:1 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cells, Cultured; Ethiopia;	2013
Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers. European journal of dermatology : EJD, 2013, Apr-01, Volume: 23, Issue:2 Topics: Adult; Aged; Amphotericin B; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis, C	2013
Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment. Infection, 2013, Volume: 41, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Female; H	2013
Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine. Journal of health, population, and nutrition, 2013, Volume: 31, Issue:2 Topics: Adult; Antiprotozoal Agents; Bangladesh; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral;	2013
Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report. Acta dermato-venereologica, 2014, Volume: 94, Issue:2 Topics: Amphotericin B; Antiprotozoal Agents; DNA, Protozoan; Drug Therapy, Combination; Humans; Leishmanias	2014
Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:1 Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily G; ATP-Binding Cassette Transporters;	2014
In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis. The Journal of parasitology, 2014, Volume: 100, Issue:6 Topics: Animals; Antiprotozoal Agents; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; Meglumine; Meglu	2014
Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis. PLoS neglected tropical diseases, 2014, Volume: 8, Issue:9 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania major; Leish	2014
Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice. Revista da Sociedade Brasileira de Medicina Tropical, 2014, Volume: 47, Issue:4 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Evaluation, Precli	2014
[Cutaneous leishmaniasis in a patient with ulcerative colitis under treatment with infliximab]. Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:9 Topics: Antiprotozoal Agents; Azathioprine; Colitis, Ulcerative; Diagnosis, Differential; Humans; Immunocomp	2015
Evaluation of the efficacy of systemic miltefosine associated with photodynamic therapy with liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL/6 mice. Photodiagnosis and photodynamic therapy, 2016, Volume: 13 Topics: Animals; Antifungal Agents; Female; Indoles; Leishmania; Leishmaniasis, Cutaneous; Liposomes; Mice;	2016
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:12 Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Appointments and Sched	2015
PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India. PLoS neglected tropical diseases, 2015, Volume: 9, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; C	2015
Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. PLoS neglected tropical diseases, 2015, Volume: 9, Issue:10 Topics: Adult; Antiprotozoal Agents; Child; Female; Histocytochemistry; Humans; India; Leishmaniasis, Cutane	2015
A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone. International journal of dermatology, 2016, Volume: 55, Issue:5 Topics: Adolescent; Adult; Amphotericin B; Antibodies, Protozoan; Antimony Sodium Gluconate; Antiprotozoal A	2016
Two cases of cutaneous leishmaniasis in Dutch military personnel treated with oral miltefosine. Journal of the Royal Army Medical Corps, 2017, Volume: 163, Issue:1 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Military	2017
Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:5 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Interactions; Drug	2016
A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome. PLoS neglected tropical diseases, 2016, Volume: 10, Issue:5 Topics: Amphotericin B; Animals; Antifungal Agents; Antiprotozoal Agents; Cricetinae; Deoxycholic Acid; Drug	2016
Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: a BMJ open, 2016, 05-17, Volume: 6, Issue:5 Topics: Adolescent; Antiprotozoal Agents; Arsenic; Bangladesh; Case-Control Studies; Child; Child, Preschool	2016
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model. The Journal of pharmacy and pharmacology, 2016, Volume: 68, Issue:7 Topics: Administration, Topical; Animals; Cells, Cultured; Disease Models, Animal; Drug Compounding; Female;	2016
In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up. PLoS neglected tropical diseases, 2016, Volume: 10, Issue:7 Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania; Leishmaniasis, Cutaneous; Mice;	2016
Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis. The American journal of tropical medicine and hygiene, 2016, Dec-07, Volume: 95, Issue:6 Topics: Adolescent; Adult; Antiprotozoal Agents; DNA, Protozoan; Female; Humans; Leishmania donovani; Leishm	2016
Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, Volume: 102, Issue:11 Topics: Adolescent; Animals; Antiprotozoal Agents; Clofazimine; Diagnosis, Differential; Humans; Hypopigment	2008
Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran. The American journal of tropical medicine and hygiene, 2008, Volume: 79, Issue:3 Topics: Adolescent; Amphotericin B; Animals; Antiprotozoal Agents; Female; Humans; Interferon-gamma; Iran; L	2008
In vivo activity of perifosine against Leishmania amazonensis. Acta tropica, 2008, Volume: 108, Issue:1 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Female; Leishmania mexicana; Leishmaniasis, Cut	2008
Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine. The American journal of tropical medicine and hygiene, 2008, Volume: 79, Issue:5 Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antiparasitic Ag	2008
Cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani. Clinical and experimental dermatology, 2009, Volume: 34, Issue:5 Topics: Animals; Antiprotozoal Agents; Facial Dermatoses; Female; Humans; Leishmania donovani; Leishmaniasis	2009
Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease. The American journal of tropical medicine and hygiene, 2009, Volume: 80, Issue:1 Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Biopsy; Bolivia; Drug Therapy, Combination; Female;	2009
Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica. Annals of tropical medicine and parasitology, 2009, Volume: 103, Issue:2 Topics: Animals; Antiprotozoal Agents; Child; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Ph	2009
Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. The American journal of tropical medicine and hygiene, 2009, Volume: 80, Issue:3 Topics: Adult; Amphotericin B; Antiprotozoal Agents; Dermatitis; Humans; Leishmaniasis, Cutaneous; Leishmani	2009
[Mucosal complication of cutaneous leishmaniasis]. Biomedica : revista del Instituto Nacional de Salud, 2009, Volume: 29, Issue:1 Topics: Aged; Anemia; Antiprotozoal Agents; Contraindications; Eyelid Diseases; Humans; Hypertension; Kidney	2009
Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:12 Topics: Amiodarone; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Synergism; Femal	2009
Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:6 Topics: Administration, Oral; Administration, Topical; Animals; Disease Models, Animal; Drug Therapy, Combin	2009
Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jan-01, Volume: 50, Issue:1 Topics: Adult; Afghanistan; Female; Humans; Leishmania major; Leishmaniasis, Cutaneous; Male; Middle Aged; M	2010
Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Annals of tropical medicine and parasitology, 2009, Volume: 103, Issue:8 Topics: Adult; Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Biopsy; Female; Humans; Leis	2009
Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment. The American journal of tropical medicine and hygiene, 2010, Volume: 82, Issue:1 Topics: Administration, Oral; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Male; Phosphor	2010
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:1 Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmanias	2010
A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis. The American journal of tropical medicine and hygiene, 2011, Volume: 84, Issue:1 Topics: Adult; Aged; Amphotericin B; Antiprotozoal Agents; Child; Female; Humans; Ketoconazole; Leishmania;	2011
Cutaneous leishmaniasis after travel to Cyprus and successful treatment with miltefosine. The American journal of tropical medicine and hygiene, 2011, Volume: 84, Issue:4 Topics: Antiprotozoal Agents; Austria; Cyprus; Female; Humans; Leishmaniasis, Cutaneous; Middle Aged; Phosph	2011
Miltefosine-induced apoptotic cell death on Leishmania major and L. tropica strains. The Korean journal of parasitology, 2011, Volume: 49, Issue:1 Topics: Animals; Apoptosis; Cell Cycle; Cell Line; DNA Fragmentation; Humans; Leishmania major; Leishmania t	2011
Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. The British journal of dermatology, 2011, Volume: 165, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Dose-Response Relationship, Drug; Dru	2011
Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. The Journal of infectious diseases, 2011, Volume: 204, Issue:9 Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; B7-1 Antigen; B7-2 Antigen; Child; Cytokines; Female;	2011
Treatment of imported New World cutaneous leishmaniasis in Germany. International journal of dermatology, 2011, Volume: 50, Issue:11 Topics: Adolescent; Adult; Aged; Amphotericin B; Animals; Antiprotozoal Agents; Female; Germany; Humans; Lei	2011
Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS neglected tropical diseases, 2011, Volume: 5, Issue:12 Topics: Antiprotozoal Agents; Female; Humans; Leishmania infantum; Leishmania major; Leishmaniasis, Cutaneou	2011
Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice. International journal of antimicrobial agents, 2012, Volume: 39, Issue:4 Topics: Animals; Antiprotozoal Agents; Azure Stains; DNA, Protozoan; Dose-Response Relationship, Drug; Drug	2012
Cutaneous leishmaniasis acquired in Jura, France. Emerging infectious diseases, 2012, Volume: 18, Issue:1 Topics: Antiprotozoal Agents; France; Humans; Leishmaniasis, Cutaneous; Male; Middle Aged; Phosphorylcholine	2012
Leishmania strains causing self-healing cutaneous leishmaniasis have greater susceptibility towards oxidative stress. Free radical research, 2012, Volume: 46, Issue:5 Topics: Antimony; Free Radicals; Humans; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral	2012
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS neglected tropical diseases, 2012, Volume: 6, Issue:5 Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Female; Humans; India; Inhibitory Concentra	2012
Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response. PLoS neglected tropical diseases, 2012, Volume: 6, Issue:7 Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Humans; Immune Evasion; Leishmania major; Lei	2012
[Leishmaniasis--oral treatment with hexadecylphosphocholine]. Wiener klinische Wochenschrift, 2004, Volume: 116 Suppl 4 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Resistance;	2004
The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. The American journal of tropical medicine and hygiene, 2005, Volume: 73, Issue:2 Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Humans; Leishmania; Leishmaniasis, Cutaneous; Leishm	2005
Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. The Journal of infection, 2006, Volume: 53, Issue:1 Topics: Adult; Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Europe; Germany; HI	2006
Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100, Issue:7 Topics: Administration, Oral; Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Humans; Injections, In	2006
Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy. Annals of tropical medicine and parasitology, 2006, Volume: 100, Issue:3 Topics: Administration, Oral; Adult; Anti-Retroviral Agents; Antiprotozoal Agents; Drug Therapy, Combination	2006
Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100, Issue:12 Topics: Administration, Oral; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Viscera	2006
Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report. International journal of dermatology, 2006, Volume: 45, Issue:6 Topics: Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Treatment Ou	2006
Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. The American journal of tropical medicine and hygiene, 2006, Volume: 75, Issue:6 Topics: Adult; Animals; Antiprotozoal Agents; Humans; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; P	2006
Hexadecyl-phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 2006, Volume: 12, Issue:5 Topics: Administration, Cutaneous; Analysis of Variance; Animals; Anti-Infective Agents, Local; Antiprotozoa	2006
First case of typical Old World cutaneous leishmaniasis treated with miltefosine. International journal of dermatology, 2007, Volume: 46, Issue:4 Topics: Administration, Oral; Adult; Animals; Antiprotozoal Agents; Diagnosis, Differential; DNA, Protozoan;	2007
[Cutaneous leishmaniasis]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2007, Volume: 58, Issue:5 Topics: Animals; Biopsy; Cross-Sectional Studies; Diagnosis, Differential; Humans; Leishmania; Leishmaniasis	2007
Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine. Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:5 Topics: Administration, Oral; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Middle Aged; Pho	2007
Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitology research, 2007, Volume: 101, Issue:5 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Humans; I	2007
Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis. Clinical and experimental dermatology, 2008, Volume: 33, Issue:1 Topics: Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosph	2008
Successful treatment of a married couple for American leishmaniasis with miltefosine. Journal of the European Academy of Dermatology and Venereology : JEADV, 2008, Volume: 22, Issue:2 Topics: Animals; Antiprotozoal Agents; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Middle Ag	2008

miltefosine and Leishmaniasis, Cutaneous